Novartis AG ADR (NVS)vsScworx Corp (WORX)
NVS
Novartis AG ADR
$147.85
+3.44%
HEALTHCARE · Cap: $282.11B
WORX
Scworx Corp
$0.46
+0.04%
HEALTHCARE · Cap: $543,980
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 1966052% more annual revenue ($56.58B vs $2.88M). NVS leads profitability with a 23.9% profit margin vs -154.4%. NVS earns a higher WallStSmart Score of 51/100 (C-).
NVS
Buy51
out of 100
Grade: C-
WORX
Hold37
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-52.5%
Fair Value
$109.60
Current Price
$147.85
$38.25 premium
Intrinsic value data unavailable for WORX.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Reasonable price relative to book value
Conservative balance sheet, low leverage
Areas to Watch
Expensive relative to growth rate
Grey zone — moderate risk
Revenue declined 0.7%
Earnings declined 9.3%
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -76.3% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bull Case : WORX
The strongest argument for WORX centers on Price/Book, Debt/Equity. Revenue growth of 13.8% demonstrates continued momentum.
Bear Case : NVS
The primary concerns for NVS are PEG Ratio, Altman Z-Score, Revenue Growth.
Bear Case : WORX
The primary concerns for WORX are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
NVS profiles as a declining stock while WORX is a turnaround play — different risk/reward profiles.
WORX carries more volatility with a beta of 2.26 — expect wider price swings.
WORX is growing revenue faster at 13.8% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 37/100), backed by strong 23.9% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Scworx Corp
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
Scworx Corp (WORX) stands at the forefront of healthcare data solutions, dedicated to optimizing clinical data management for healthcare providers and stakeholders. Utilizing cutting-edge technology, the company enhances operational efficiency and bolsters the quality of care through robust analytics, empowering institutions to make informed, data-driven decisions. With a strategic focus on scalability and innovation, Scworx is well-positioned to meet the growing demand for data-centric solutions in the healthcare sector, thereby improving patient outcomes and enabling effective cost management. This commitment to transforming healthcare delivery solidifies Scworx's critical role in the rapidly evolving healthcare landscape.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?